Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ELCC-2022-1000x250

The abstract submission is now open

Submit your abstract

Abstract submission deadlines

Deadline

Date and time

  • Abstract 
  • Trial in Progress
  • Intent to submit LBA

Monday, 17 January 2022, 21:00 CET (Central European Time)

  • Late-breaking abstracts (LBA)

Tuesday, 01 March 2022, 21:00 CET (Central European Time)

Submission categories

  • Tumour biology and pathology
  • Translational research
  • Prevention, early detection, epidemiology, tobacco control
  • Imaging and staging
  • SCLC
  • Early stage NSCLC
  • Locally advanced NSCLC
  • Advanced NSCLC
  • Metastases to and from the lung
  • Mesothelioma
  • General interest

Late-breaking abstracts (LBA) 

Late-breaking abstracts may be submitted for high quality, new research findings from randomised phase II or phase III trials with implications for clinical practice or understanding of disease processes.  

Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 17 January 2021 will be considered for late-breaking status. The work must not have been previously published in any publication in a peer review setting or presented at a meeting of any other scientific organisation prior to the ELCC 2022.

A skeleton indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by the regular abstract deadline on of Monday, 17 January 2022.   

Submitters of preliminary versions receiving approval to proceed must submit the final LBA by Tuesday, 01 March 2022

Trial in progress abstracts

Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to ELCC 2022

It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis and consequently will only require the completion of two (2) sections:

  • Background
  • Trial design

Notes:

  • Recruitment must have already begun or have been completed by the abstract submission deadline of 17 January 2022.
  • Abstracts including results or preliminary data will be rejected.
  • Trial in Progress abstracts will not be considered for Proffered Paper (oral) presentation or Mini Oral.
  • Encore TiP abstracts will NOT be accepted.

Presentation options for accepted abstracts 

The ELCC 2022 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:

  • Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
  • Mini Oral – Short oral presentation by authors with comment and interactive audience discussion led by an invited expert.
  • Poster – Display session for review, discussion and questions.

All accepted abstracts will be published in the ELCC 2022 Abstract book, a supplement to the official ESMO journal, Annals of Oncology.

Travel Grants

A limited number of Travel Grants are available, upon application, to first authors under the age of 40 who submit abstracts considered deserving of recognition. Selection will be made by ELCC 2022 Scientific Committee on a competitive basis from among the accepted abstracts.

More information can be found in the Abstract regulations.

Publication schedule

The publication schedule for accepted abstracts will be released in due course.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings